Astrazeneca Ab

Oblique Therapeutics Ab

Kjell Andersson

Tord Bertil Inghardt

Eva-Lotte Lindstedt Alstermark

Maria Boije

Benjamin Pelcman

Owe Orwar

Lanna Li

Jan-Erik Nystr&ouml;m

Eva-Lotte Lindstedt-Alstermark

Marcel Linschoten

Olle Karlsson

Johan Gottfries

William Stafford

Eva-Lotte Lindstedt

Panagiotis Ioannidis

Magnus Larsson

Sivaprasad Sivadasan

Henrik Sorensen

Gunnel Sund&eacute;n

Bo Nord&eacute;n

Bengt Ljung

Alan Eric Fischer

Maria Larsson

There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R, R, R, Rand n have meanings provided in the description, which compounds are useful in the treatment of cancers. 

Sulfinylpyridines and their use in the treatment of cancer

The present invention provides a process for the preparation of substantially racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid which comprises reacting 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid enriched in one enantiomer with a base in an inert solvent.

Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid

The present invention relates to novel resolution methods, which are useful in the preparation of enantiomerically enriched intermediates which in their turn are useful in the prepartion of compounds with a pharmacological effect on the insulin resistance syndrome (IRS). It is such a process that the present inventions sets out to define, and more particularly for the preparation of the (S)-enantioner of certain 2-ethoxy-3-(4-hydroxyphenyl)propanoic acids and derivatives thereof.

Process for the preparation on enantiomerically enriched compounds

Thiochromane derivatives and their use as thrombin inhibitors

A novel 3-aryl-2-hydroxypropionic acid derivative, a process and intermediate for its manufacture, pharmaceutical preparations containing it and the use of the compound in clinical conditions associated with insulin resistance.

3-aryl-2-hydroxypropionic acid derivative I

Novel 3-aryl propionic acid derivatives and analogs, process and intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance.

3-aryl propionic acid derivatives and analogs

A novel 3-aryl-2-hydroxypropionic acid derivative, a process and intermediate for its manufacture, pharmaceutical prepartions containing it and the use of the compound in clinical conditions associated with insulin resistance.

3-aryl-2-hydroxypropionic acid derivative III

Novel thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives, process for their manufacture, pharmaceutical preparations containing them and the use of the compounds in conditions associated with insulin resistance.

Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives

3-aryl-2-hydroxypropionic acid derivative (I)

Growing community of inventors

Fjärås, Sweden

Kjell Andersson